CEO Executive AssistantHealth technology assessment has become one of the most consequential commercial gatekeeping processes that pharmaceutical companies face in developed markets. In the United Kingdom, NICE (National Institute for Health and Care Excellence) conducts technology appraisals that determine NHS coverage and reimbursement. In Germany, the G-BA (Gemeinsamer Bundesausschuss) conducts early benefit assessments that determine whether a new drug has added benefit over existing therapy, and the magnitude of that benefit, which in turn drives price negotiations with statutory health insurance funds. In France, HAS (Haute Autorité de Santé) conducts ASMR assessments that classify the degree of therapeutic improvement offered by a new medicine.
Pharma CEO health technology assessment time management is strategically urgent because HTA outcomes have direct commercial consequences. A NICE rejection limits access to the NHS market, which despite its lower drug prices represents significant volume for many therapeutic categories. A G-BA assessment of “no additional benefit” (Zusatznutzen) triggers mandatory reference pricing to generic comparators, which can reduce a drug’s German price by 50 to 70 percent. An HAS ASMR V rating (no clinical benefit improvement) undermines the commercial case in France.
Why HTA Requires CEO-Level Attention
HTA agencies make reimbursement decisions using evidence frameworks that are different from FDA or EMA approval frameworks. Regulatory agencies approve drugs based on evidence of safety and efficacy compared to placebo or active comparator in controlled clinical trials. HTA agencies assess comparative effectiveness against the specific standard of care in their national healthcare system, using evidence standards that often go beyond the regulatory submission data package.
The most important divergence: HTA agencies frequently require indirect comparisons (network meta-analyses comparing the new drug to standard of care even when head-to-head trial data do not exist), patient-level economic modeling (cost-utility analyses using quality-adjusted life years as the primary outcome), and evidence of real-world effectiveness in the specific national patient population.
These requirements are not afterthoughts: they must be anticipated in the clinical development program design. A Phase 3 trial that uses a placebo control when the standard of care includes active therapy may satisfy FDA for approval but will generate inadequate comparator evidence for NICE technology appraisal. A trial that measures disease-free survival rather than overall survival or quality of life may satisfy EMA for marketing authorization but will not provide the HRQoL data that HAS requires for ASMR assessment.
The CEO who understands this divergence ensures that the Phase 3 program design is planned for both regulatory approval and HTA success, not just regulatory approval. This requires CEO engagement in clinical trial design at a stage when HTA outcomes are still 10 years away, but when the evidence generation decisions that determine HTA outcomes are being made.
NICE Technology Appraisal: The UK Market Access Process
NICE conducts technology appraisals using an incremental cost-effectiveness ratio (ICER) threshold: drugs that offer cost-effectiveness below approximately £20,000 to £30,000 per quality-adjusted life year (QALY) are typically recommended for NHS coverage; drugs above this threshold are typically not recommended without a Patient Access Scheme or Commercial Access Agreement that adjusts the effective price.
The NICE technology appraisal process requires:
A company submission document. The company submits a detailed dossier covering: clinical evidence, including systematic literature reviews and indirect treatment comparisons; a cost-effectiveness model; and patient and clinical perspective materials. This submission requires significant investment in health economics and outcomes research (HEOR) capability.
Cost-effectiveness modeling. The economic model must project the cost and effectiveness of the new drug versus the NICE comparator over a lifetime horizon, using utility weights (health state preferences) that are validated for the relevant disease population. Economic model credibility is determined by the transparency of the model structure, the appropriateness of the data sources, and the reasonableness of the model assumptions.
Patient access scheme negotiation. When the base-case ICER exceeds NICE’s threshold, the company can negotiate a patient access scheme with NHS England that adjusts the effective price (through rebates, outcomes-based payments, or patient access restrictions) to bring the ICER within acceptable range. Patient access scheme negotiations are commercial negotiations that require CEO-level strategic direction.
NICE’s technology appraisal process describes the procedural framework within which companies submit evidence and respond to NICE committee reviews. CEOs should be familiar with the timeline: a NICE appraisal typically takes 12 to 18 months from company submission to final guidance.
For context on how international regulatory submissions integrate with the CEO’s overall time architecture, see global regulatory submissions time management.
G-BA Early Benefit Assessment: Germany’s Distinctive Framework
Germany’s AMNOG (Arzneimittelmarktneuerungsgesetz) process requires pharmaceutical companies to submit a benefit dossier to G-BA within three months of a new drug receiving EU marketing authorization. G-BA then conducts an early benefit assessment, evaluating whether the new drug has additional benefit compared to the “appropriate comparator therapy” (zweckmäßige Vergleichstherapie, or ZVT) that G-BA defines for the indication.
The G-BA process has several distinctive features that require CEO-level understanding:
G-BA defines the comparator, not the company. The company must engage with G-BA proactively, through a formal “Beratungsanforderung” (advice request) process, to understand what comparator G-BA will use for the benefit assessment. If the Phase 3 trial was designed with a different comparator than G-BA’s ZVT, the company may face an indirect comparison problem that weakens the benefit assessment outcome.
Benefit rating categories. G-BA assigns one of six benefit ratings: major additional benefit (erheblicher Zusatznutzen), considerable additional benefit (beträchtlicher Zusatznutzen), minor additional benefit (geringer Zusatznutzen), non-quantifiable additional benefit (nicht quantifizierbarer Zusatznutzen), no additional benefit proven (kein Zusatznutzen belegt), or less benefit. A rating of “no additional benefit” triggers mandatory reference pricing.
Price negotiation. Following the benefit assessment, the company negotiates price with GKV-Spitzenverband (the association of statutory health insurance funds). The benefit rating is the primary input to this negotiation: a higher benefit rating supports a higher price. The CEO’s involvement in G-BA pricing negotiations is strategic: setting the negotiating position, deciding when to accept a negotiated price versus invoke arbitration.
Opt-out option. Companies that receive an unfavorable G-BA benefit rating can opt out of the German market rather than accept mandatory reference pricing. This is a CEO-level strategic decision with significant commercial, reputational, and patient access implications.
HAS Assessment: French Market Reimbursement
In France, HAS (Haute Autorité de Santé) conducts two assessments relevant to pharmaceutical reimbursement. The Transparency Commission evaluates the “service médical rendu” (SMR, medical benefit) and “amélioration du service médical rendu” (ASMR, improvement in medical benefit). SMR determines eligibility for reimbursement and the reimbursement rate; ASMR determines the degree of therapeutic improvement, which drives price negotiations with the CEPS (Comité économique des produits de santé).
ASMR ratings run from I (major improvement) to V (no improvement). An ASMR I or II enables premium pricing negotiations; ASMR IV or V results in pricing at the level of the most economical comparator. The CEO’s engagement with HAS submission strategy is therefore directly relevant to French pricing outcomes.
HEOR Organizational Capability: The CEO’s Investment Decision
HTA success depends on a capable Health Economics and Outcomes Research function. The HEOR organization provides the economic modeling, systematic literature review, indirect treatment comparison, and health-related quality of life data that NICE, G-BA, HAS, and other HTA bodies evaluate. An underfunded or underexperienced HEOR function produces HTA submissions that are technically adequate but not compelling, resulting in more restrictive coverage decisions than the clinical evidence would support.
The CEO’s HEOR investment decisions:
Building versus buying HEOR capability. Most pharmaceutical companies access HEOR expertise through a combination of internal staff and external CRO-type HEOR consultancies. The CEO must ensure the organization has access to HEOR capability that matches the complexity of the HTA submissions it needs to produce.
Early HEOR integration. HEOR should be integrated into the Phase 2 and Phase 3 clinical development team as standard practice, not engaged at the NDA/BLA submission stage when the evidence package is already fixed. The CEO who mandates early HEOR integration ensures that clinical development design decisions account for HTA evidence requirements.
Country-specific HEOR expertise. NICE, G-BA, and HAS have different evidence requirements, different acceptable economic modeling approaches, and different submission standards. The CEO should ensure the HEOR function has genuine country-specific expertise rather than a generic approach to all HTA submissions.
Early Scientific Advice: The CEO’s Access to HTA Dialogue
Most major HTA bodies offer early scientific advice (ESA) programs that allow pharmaceutical companies to discuss their clinical development program and evidence generation plan before Phase 3 initiation. EMA and NICE jointly offer parallel scientific advice. G-BA offers early dialogue for Phase 3 design. HAS offers early access interactions.
The CEO should ensure the organization systematically uses these early advice opportunities for programs in major EU markets. Early scientific advice with NICE and G-BA can identify potential HTA problems in the clinical trial design before Phase 3 begins, when corrective action is still possible. The cost of these interactions is trivial compared to the commercial impact of an unfavorable HTA outcome due to an avoidable evidence gap.
Time Architecture for HTA Governance
A practical time architecture for pharma CEO health technology assessment time management:
Development program integration. HTA planning should be standard agenda content in Phase 2 portfolio reviews and Phase 3 program design meetings. For any program targeting EU markets, the G-BA ZVT engagement and NICE comparable care definition should be identified before Phase 3 initiation.
HTA submission milestone governance. For programs approaching regulatory approval and HTA submission simultaneously, the CEO should have visibility into the HTA submission timeline and should review the evidence package and economic model at a governance level before submission.
Pricing negotiation involvement. For G-BA and HAS pricing negotiations with strategic significance, the CEO should set the negotiating parameters and should be directly informed of negotiation progress and outcomes.
Country-specific access reviews. Quarterly reviews of market access status across major EU markets, covering NICE appraisal status, G-BA assessment outcomes, HAS ASMR ratings, and access outcomes in other priority markets (Spain, Italy, Netherlands).
Conclusion
Pharma CEO health technology assessment time management requires sustained strategic engagement with evidence planning that begins at Phase 2 and continues through post-marketing. The HTA frameworks in the UK, Germany, and France create evidence requirements that can only be met if the clinical development program is designed with HTA success as an explicit objective. CEOs who govern HTA planning as an integrated element of the development strategy, who invest in genuine HEOR capability, and who engage HTA agencies through early scientific advice processes will achieve better market access outcomes than those who treat HTA as a post-approval commercial problem. The commercial value at stake in major EU markets justifies CEO-level attention throughout the development timeline.
Related Reading
For further context, explore Time Management for Animal Health Pharma CEOs and Biologics CEO Time Management: Navigating Manufacturing Complexity.